Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia

NCT ID: NCT07245056

Last Updated: 2025-12-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

84 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-01

Study Completion Date

2026-08-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since early-onset preeclampsia (EOPE) is commonly associated with inadequate placentation, placental insufficiency, chronic fetal hypoxia, oxidative stress, and heightened inflammation, these pathological processes may adversely affect hippocampal neuronal development and maturation of axonal pathways such as the fornix. These mechanisms support our hypothesis that fetal fornix and hippocampus dimensions may be reduced in pregnancies complicated by EOPE, forming the scientific basis of our study.

Previous research has suggested a potential link between preeclampsia (PE) and altered neurocognitive development. However, no studies to date have specifically evaluated the relationship between EOPE and fetal fornix or hippocampus dimensions. Therefore, the objective of our study is to assess fetal fornix and hippocampus measurements in pregnant women with early-onset preeclampsia compared with healthy controls.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hypertensive disorders complicate approximately 5-10% of all pregnancies and account for nearly 16% of maternal mortality. Preeclampsia (PE) occurs in 4-5% of pregnancies, and in the United States, preeclampsia or eclampsia contributed to 7.4% of the 2,009 pregnancy-related maternal deaths reported between 2011 and 2013. Preeclampsia is defined by new-onset hypertension and proteinuria, or new-onset hypertension with or without proteinuria, accompanied by evidence of significant end-organ dysfunction. It is a progressive, multisystem disorder that generally develops after 20 weeks of gestation or during the postpartum period.

Preeclampsia is also considered a pregnancy-specific syndrome capable of affecting every organ system. Because of its significant maternal and perinatal morbidity and mortality, PE represents a major public health concern. The condition is commonly described as a two-stage disease. Stage 1 (placental syndrome) is characterized by early placental ischemia/reperfusion, oxidative stress, and the release of toxic factors, primarily due to abnormal endovascular trophoblastic remodeling, primigravidity, trophoblast load, genetic predisposition, and maternal immunologic maladaptation. Stage 2 (maternal syndrome) represents the clinical phase, driven by an exaggerated maternal systemic inflammatory response and endothelial dysfunction. Maternal genetic susceptibility and underlying vascular disease may further contribute.

Overall, the etiopathogenesis of PE involves abnormal trophoblastic invasion, maternal-fetal immunologic incompatibility, maladaptation to normal cardiovascular and inflammatory changes of pregnancy, systemic vascular dysfunction, genetic influences, and epigenetic mechanisms. Approximately 90% of preeclampsia cases occur in the late-preterm (34-37 weeks), term, or postpartum period and generally have more favorable outcomes. However, severe morbidity and mortality may still occur. The remaining 10% of cases present as early-onset preeclampsia (EOPE, \<34 weeks), in which abnormal placentation and defective trophoblastic invasion are more pronounced and closely correlate with disease severity. EOPE carries a markedly higher risk of serious perinatal complications, largely due to its strong association with preterm delivery. Consequently, the study of EOPE remains clinically important.

The hippocampus is a seahorse-shaped structure located within the medial temporal lobe, protruding laterally toward the temporal horn of the lateral ventricle. It plays essential roles in memory processing (dorsal hippocampus) and regulation of stress responses (ventral hippocampus). Fetal hippocampal development involves progressive inward folding of the dentate gyrus, cornu ammonis, subiculum, and parahippocampal gyrus around the shrinking hippocampal sulcus.

Experimental studies have demonstrated that adverse maternal conditions may affect hippocampal development. In rodent models, uncontrolled maternal diabetes reduces hippocampal volume and neuronal density during early postnatal life, leading to delayed development and motor, behavioral, and cognitive deficits in offspring. In an experimental preeclampsia model induced with a cholesterol-based diet, hippocampal arteriolar vasoreactivity to neurovascular coupling mediators was impaired, resulting in deficits in long-term-but not spatial-memory. These findings may parallel long-term cardiovascular and neurocognitive outcomes observed in women with a history of preeclampsia and eclampsia. Persistent endothelial and vascular smooth muscle dysfunction in hippocampal vessels may contribute to disrupted hippocampal networks and early cognitive impairment.

Clinical and experimental data also suggest that children born to preeclamptic mothers have higher rates of neurodevelopmental disorders, including cognitive impairments, autism spectrum disorder, depressive disorders, attention-deficit/hyperactivity disorder, and cerebral palsy. Reported neuronal abnormalities include impaired neurogenesis, reduced neuronal integrity, accumulation of cellular debris, decreased synaptogenesis and myelination, and abnormal neurite outgrowth, potentially mediated by microglial activation, inflammation, and reduced angiogenesis.

Since EOPE is frequently associated with inadequate placentation, placental insufficiency, chronic fetal hypoxia, oxidative stress, and inflammation, these pathophysiologic processes may interfere with fetal hippocampal neuronal development and maturation of the fornix. These mechanisms support our hypothesis that fetal fornix and hippocampus dimensions may be reduced in EOPE.

Ultrasonographic literature on fetal hippocampal imaging is limited. Gindes et al. demonstrated that the fetal hippocampus and fornix can be identified as a C-shaped structure on sagittal three-dimensional (3D) ultrasound. Toprak et al. reported that the fetal fornix and hippocampus can be rapidly visualized using two-dimensional (2D) ultrasound during midtrimester anomaly screening. Sahin et al. confirmed that the bilateral fornix-hippocampus complex can be visualized between 18 and 36 weeks of gestation and proposed sonographic reference values.

Research Hypothesis:

Is there a difference in fetal fornix and hippocampus dimensions in pregnancies complicated by early-onset preeclampsia compared with healthy controls? Our primary hypothesis is that fetal fornix and hippocampus dimensions are reduced in EOPE.

Expected Benefits:

By assessing the relationship between fetal fornix and hippocampus size and EOPE, and evaluating potential associations with pregnancy prognosis and complications, this study may contribute to improved understanding and management of the condition and support future prospective research. The study poses no risk to pregnant women or fetuses.

The study will enroll 42 pregnant women diagnosed with EOPE (aged 18-45 years, 20-34 weeks of gestation) presenting to the Perinatology Clinic of Ankara Etlik City Hospital, along with 42 healthy controls. Sample size calculation using G\*Power 3.1.9.7 indicated that a minimum of 84 participants would provide 95% statistical power (effect size d = 0.8, α = 0.05, 1-β = 0.95). Participants will be included after informed consent is obtained, and confidentiality will be ensured.

Demographic and routinely collected clinical data-including age, gestational age, height, weight, BMI, weight gain, gravidity, parity, obstetric history, comorbidities, medications, prior surgeries, tobacco and alcohol use-will be recorded. Routine laboratory parameters and ultrasonographic measurements (biometry, amniotic fluid index, umbilical artery Doppler systolic/diastolic (S/D) ratio and pulsatility index (PI), middle cerebral artery Doppler peak systolic velocity (PSV) and PI, uterine artery Doppler PI, cerebroplacental ratio (CPR), and cerebro-placento-uterine ratio (CPUR)) will also be obtained.

For this study, fetal fornix and hippocampus dimensions will be measured by 2D ultrasound in both EOPE and control groups using standard clinic equipment. All findings will be compiled into a detailed report including statistical analyses, comparisons between groups, and evaluation of the relationship between EOPE and fetal fornix/hippocampus measurements.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pre-Eclampsia Hippocampus

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

fetal brain fornix hippocampus early-onset preeclampsia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

One arm (fetal FHC measurements for EOPE and control groups)

One arm for fetal fornix and hippocampus complex (FHC) measurements on early-onset preeclampsia (EOPE) and control groups

Group Type OTHER

FHC dimensions in EOPE and control groups

Intervention Type OTHER

Fetal fornix and hippocampus complex (FHC) dimension changes on EOPE and control groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FHC dimensions in EOPE and control groups

Fetal fornix and hippocampus complex (FHC) dimension changes on EOPE and control groups

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged 18-45 years
* Gestational age between 20 and 34 weeks
* Diagnosis of early-onset preeclampsia (EOPE)
* Singleton pregnancy

Exclusion Criteria

* Multiple pregnancies
* Presence of chronic or significant comorbid conditions other than maternal early-onset preeclampsia, including: Chronic, mental, or physical illnesses, severe renal, hepatic, or gastrointestinal acute or chronic inflammatory diseases, hyperthyroidism or hypothyroidism, chronic hypertension, type 1 or type 2 diabetes mellitus, history of polycystic ovary syndrome (PCOS), history of malignancy
* Fetal congenital or chromosomal anomalies
* Chronic medication use
* Tobacco or alcohol use during pregnancy
* Maternal late-onset preeclampsia (≥34 weeks gestation)
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ankara Etlik City Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Seyit Ahmet Erol

Associate Professor, MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Seyit A Erol, MD

Role: PRINCIPAL_INVESTIGATOR

Ankara Etlik City Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ankara Etlik City Hospital

Ankara, Yenimahalle, Turkey (Türkiye)

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Seyit A Erol, MD

Role: CONTACT

Phone: +0903127970000

Email: [email protected]

Kadriye Yakut Yucel, MD

Role: CONTACT

Phone: +0903127970000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Seyit A Erol, MD

Role: primary

Kadriye Yakut Yucel, MD

Role: backup

References

Explore related publications, articles, or registry entries linked to this study.

Zhang H, Lin J, Zhao H. Impacts of Maternal Preeclampsia Exposure on Offspring Neuronal Development: Recent Insights and Interventional Approaches. Int J Mol Sci. 2024 Oct 15;25(20):11062. doi: 10.3390/ijms252011062.

Reference Type BACKGROUND
PMID: 39456854 (View on PubMed)

Johnson AC, Li Z, Orfila JE, Herson PS, Cipolla MJ. Hippocampal network dysfunction as a mechanism of early-onset dementia after preeclampsia and eclampsia. Prog Neurobiol. 2021 Apr;199:101938. doi: 10.1016/j.pneurobio.2020.101938. Epub 2020 Oct 29.

Reference Type BACKGROUND
PMID: 33130230 (View on PubMed)

Johnson AC, Tremble SM, Cipolla MJ. Experimental Preeclampsia Causes Long-Lasting Hippocampal Vascular Dysfunction and Memory Impairment. Front Physiol. 2022 May 9;13:889918. doi: 10.3389/fphys.2022.889918. eCollection 2022.

Reference Type BACKGROUND
PMID: 35615682 (View on PubMed)

Sadeghi A, Asghari H, Hami J, Mohasel Roodi M, Mostafaee H, Karimipour M, Namavar M, Idoon F. Volumetric investigation of the hippocampus in rat offspring due to diabetes in pregnancy-A stereological study. J Chem Neuroanat. 2019 Nov;101:101669. doi: 10.1016/j.jchemneu.2019.101669. Epub 2019 Aug 20.

Reference Type BACKGROUND
PMID: 31442582 (View on PubMed)

Arica G, Davutoglu EA, Buldum D, Kucuksuleymanoglu D, Najmeddin S, Madazli R. Fetal Fornix-Hippocampus Complex and Hippocampus Height Measurements Between 18 and 24 Weeks of Gestation and the Effect of Maternal Iron Deficiency Anemia. J Clin Ultrasound. 2025 Jul-Aug;53(6):1288-1295. doi: 10.1002/jcu.24008. Epub 2025 Apr 16.

Reference Type RESULT
PMID: 40237113 (View on PubMed)

Gindes L, Weissmann-Brenner A, Weisz B, Zajicek M, Geffen KT, Achiron R. Identification of the fetal hippocampus and fornix and role of 3-dimensional sonography. J Ultrasound Med. 2011 Dec;30(12):1613-8. doi: 10.7863/jum.2011.30.12.1613.

Reference Type RESULT
PMID: 22123994 (View on PubMed)

Sahin NE, Alici Davutoglu E, Arica G, Madazli R. Identification of bilateral fornix and hippocampus in fetuses between 18-36 gestational weeks and establishment of nomograms using ultrasonography. Arch Gynecol Obstet. 2025 Aug;312(2):627-634. doi: 10.1007/s00404-025-08061-z. Epub 2025 May 23.

Reference Type RESULT
PMID: 40407880 (View on PubMed)

Toprak E, Sayal HB. Ultrasonographic imaging of the fetal hippocampus. Arch Gynecol Obstet. 2024 May;309(5):1943-1949. doi: 10.1007/s00404-023-07093-7. Epub 2023 Jun 9.

Reference Type RESULT
PMID: 37294452 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AEŞH-BADEK2-2025-551

Identifier Type: -

Identifier Source: org_study_id